InFarmatik - founded in 1994 by Dr. Laszlo Kovacs - offers a continuously growing collection of non-exclusive building blocks, scaffolds and advanced intermediates. Its diverse portfolio includes a wide range of compounds from benzodiazepines through modern TOSMIC building blocks to unique structures. The scaffolds are designed to provide convenient starting materials for drug molecules in therapeutic applications for CNS and oncology and inhibitors zinc coordinating enzymes (MMPs, ADAMs).. InFarmatik follows an aggressive synthetic method development strategy employing its proprietary thermal gradient platform. Worlwide In 2003 InFarmatik established a subsidiary in the US (InFarmatik, Inc. ) in order to facilitate the co-operation with North American partners. In October 2006 InFarmatik Inc. appointed Barry Feigelman (bfeigelman@infarmatik.com) exclusive USA and Canadian sales representative. In August 2008, Michael Bossert (mbossert@infarmatik.hu) was promoted to the position Sales Director, Europe & Asia, after having joined the company in February 2008 and Director of European Sales. In Asia, English speaking researchers can contact him directly; while our Japanese speaking colleagues can contact our non exclusive distributor, Namiki Shoji, Co. Ltd. (info@namiki-s.co.jp).